clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Wheeldon TU et al. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. 2003 Aliment. Pharmacol. Ther. pmid:12848630
Lai KC et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. 2003 Aliment. Pharmacol. Ther. pmid:14535877
Kamberoglou D et al. Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. 2001 Aliment. Pharmacol. Ther. pmid:11552924
al-Assi MT et al. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:7986970
Okudaira K et al. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. 2005 Aliment. Pharmacol. Ther. pmid:15710002
Lai KC et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. 2003 Aliment. Pharmacol. Ther. pmid:12641502
Wong BC et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. 2000 Aliment. Pharmacol. Ther. pmid:10651663
Fock KM et al. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. 2000 Aliment. Pharmacol. Ther. pmid:10651664
Yousfi MM et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. 1995 Aliment. Pharmacol. Ther. pmid:7605865
Choi IJ et al. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:11856089
Qasim A and O'Morain CA Review article: treatment of Helicobacter pylori infection and factors influencing eradication. 2002 Aliment. Pharmacol. Ther. pmid:11849124
Cestari R Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. 1998 Aliment. Pharmacol. Ther. pmid:9798804
Grimley CE et al. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. 1999 Aliment. Pharmacol. Ther. pmid:10383520
Spadaccini A et al. Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9798805
Villoria A et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. 2008 Aliment. Pharmacol. Ther. pmid:18644011
Leiper K et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. 2008 Aliment. Pharmacol. Ther. pmid:18315579
Thung I et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. 2016 Aliment. Pharmacol. Ther. pmid:26694080
Tankovic J et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. 2001 Aliment. Pharmacol. Ther. pmid:11328266
Zullo A et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. 2007 Aliment. Pharmacol. Ther. pmid:17539982
Nista EC et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. 2004 Aliment. Pharmacol. Ther. pmid:15569121